A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Clinical trial NCT05683977 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05683977
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2022-11-14
- Primary completion
- 2027-03-01
- Enrollment
- 254
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.